# Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

> **NCT06885697** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 100 (estimated)

## Conditions studied

- Mesothelioma
- Neoplasms
- Stomach Neoplasms
- Pancreatic Neoplasms
- Ovarian Neoplasms
- Lung Neoplasms
- Thymus Neoplasms
- Colonic Neoplasms

## Interventions

- **DEVICE:** mesothelin expression testing
- **BIOLOGICAL:** TNhYP217 CAR T Cells
- **DRUG:** fludarabine
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT06885697
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2034-06-01
- **Final completion:** 2044-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06885697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06885697, "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06885697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*